FDA Updates Articles
The U.S.Food and Drug Administration has approved a supplemental Biologics License Application to extend the shelf life of Hizentra.
The U.S. Food and Drug Administration (FDA) has approved Benlysta (belimumab) to treat patients with active autoantibody positive lupus (systemic lupus erythematosus) who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives and non steroidal anti-inflammatory drugs.
Prolastin-C has been approved by the Food and Drug Administration for the treatment of alpha1-antitrypsin (AAT)deficiency.
The Food and Drug Administration has approved two new drugs for the treatment of acute attacks of hereditary angioedema.
The U.S.Food and Drug Administration has approved wilate for the treatment of spontaneous and trauma-induced bleeding episodes in patients with all types of von Willebrand disease.